Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
59 Results for "
Keap1/Nrf2 pathway
" in MedChemExpress (MCE) Product Catalog:
Products (59)
59 Results for "Keap1/Nrf2 pathway" in MCE Product Catalog:
77
8
Category:
Alkaloids Evodia rutaecarpa (Juss.) Benth. Rutaceae Plants Disease Research Fields Cancer Indole Alkaloids
Target:
6
6 Cited Publications
Synonyms: Methylmaleic acid; Citraconate
4
4 Cited Publications
Cat. No.: HY-N0806
CAS No.: 14215-86-2
2
2 Cited Publications
Synonyms: L-Sulforaphane
2
2
2
2 Cited Publications
Cat. No.: HY-N11849
CAS No.: 135248-05-4
Category:
2
Research Areas:
Vialinin A (Terrestrin A) is a p-terphenyl compound that can be derived from a Chinese edible mushroom. Vialinin A is an inhibitor of ubiquitin-specific peptidase 4 (USP4) and has anti-inflammatory and antioxidant properties. Vialinin A can alleviate cerebral ischaemia-reperfusion injury-induced neurological deficits and neuronal apoptosis. Vialinin A promotes activation of Keap1-Nrf2-ARE signaling pathway and increases the protein degradation of Keap1. Vialinin A possesses various pharmacological activities in cancer, Kawasaki disease, asthma, and pathological scarring. Vialinin A is a potent inhibitor of TNF-α, USP4, USP5, and sentrin/SUMO-specific protease 1 (SENP1). Vialinin A can be studied in reseach for autoimmune diseases, cancer and ischaemic stroke .
1
1
1 Cited Publications
Cat. No.: HY-P2048
CAS No.: 1627580-64-6
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
1
1 Cited Publications
Target:
Research Areas:
K67 is a selective the interaction between Keap1 and S349 phosphorylated p62 inhibitor, with an IC50 of 1.5 μM. K67 has a weaker inhibitory effect on the interaction between Keap1 and Nrf2 (IC50 is 6.2 μM). K67 competitively binds to the binding site of Keap1 with p-p62, blocking the abnormal activation of the p62-dependent Nrf2 pathway. K67 inhibits tumor cell proliferation and enhances the sensitivity of hepatocellular carcinoma (HCC) to chemotherapeutic drugs by restoring Keap1-mediated ubiquitination and degradation of Nrf2 .
1
1
Category:
Flavonols Cupressaceae Flavonoids Neurological Disease Thuja occidentalisLinn. Plants Disease Research Fields Inflammation/Immunology
Target:
1
1 Cited Publications
Cat. No.: HY-W338584
CAS No.: 232281-44-6
1
1 Cited Publications
Cat. No.: HY-N0008
CAS No.: 21082-33-7
Target:
1
1 Cited Publications
Research Areas:
CPUY192018 is a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, with an IC50 of 0.63 µM. CPUY192018 exhibits anti-inflammatory and antioxidant activities. CPUY192018 can activate the Nrf2-dependent antioxidant pathway and inhibit the NF-κB-related inflammatory response. CPUY192018 can be used in the research of inflammation-related diseases .
1
1 Cited Publications
Cat. No.: HY-P2048A
Research Areas:
Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
Target:
Research Areas:
RA839 is a selective Nrf2/ARE pathway agonist and non-covalent small molecule binder of Keap1 (Kd is approximately 6 μM). RA839 prevents inducible nitric oxide synthase expression and nitric oxide release. RA839 exerts anti-rotaviral and anti-inflammatory effects .
Cat. No.: HY-171705
CAS No.: 1478585-60-2
Research Areas:
KMS99220 is an orally active, blood-brain barrier-permeable activator of the Nrf2 inhibitory protein Keap-1. KMS99220 enhances the activity of AMPK, activates the Nrf2 signaling pathway, and reduces the phosphorylation of IκB, nuclear translocation of NFκB, as well as the phosphorylation levels of JNK, IKK and p38 MAPK via HO-1. KMS99220 binds to Keap1 to trigger the nuclear translocation of Nrf2, induces the expression of HO-1, NQO1, GCLC, GCLM and proteasome subunits; enhances proteasomal enzymatic activity; inhibits iNOS expression, nitric oxide production and IL-1β generation; attenuates microglial activation; reduces α-synuclein aggregation; and prevents dopaminergic neuron degeneration and motor dysfunction. KMS99220 prevents the degeneration of dopaminergic neurons in the substantia nigra, induces the expression of Nrf2 downstream target genes, and effectively ameliorates associated motor dysfunction in a mouse model of Parkinson's disease. KMS99220 is applicable to research related to Parkinson's disease .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
